단일기관에서 미숙아 폐출혈에서의 유전자재조합 활성화 제 7인자 사용 경험 = Use of Recombinant Activated Factor VII for Pulmonary Hemorrhage in Premature Infants: A Single-Center Experience

다국어 초록 (Multilingual Abstract)

Background: Pulmonary hemorrhage in prematurity is a life-threatening complication and associated with a high mortality. Recombinant activated factor VII (rFVIIa) has been reported as hemostatic treatment in sick neonates with refractory bleeding events in many studies. We evaluated the efficacy and safety of rFVIIa in prematurity with pulmonary hemorrhage in our institution.
Methods: From the prematurities who were treated with rFVIIa to pulmonary hemorrhage from January 2010 to December 2015, we retrospectively analyzed the results of rFVIIa.
Results: Of the 29 prematurities who were treated with rFVIIa for pulmonary hemorrhage, fifteen were male and fourteen were female. The median gestational age was 27 1/7 weeks (range, 22 1/7-34 1/7 weeks) and median birth weight was 870 g (range, 470-2,070 g). One to eight doses of rFVIIa (median dose 115.6 g/kg/dose) were administered, with 16 (55%) patients receiving a single dose. Hemostatic effect was achieved in 21 (72.4%) cases, but 6 of 21 patients died of unrelated cause, and overall mortality was 14 of 29 (48.3%). Thrombotic adverse event was not observed in any of our patients.
Conclusion: Although the number of patients included in this study was small and the fact that this was a retrospective non-randomized control study, rFVIIa could be considered as a therapeutic option for pulmonary hemorrhage in prematurity.

참고문헌 (Reference)

1 Lichtman MA, "Williams hematology" McGraw-Hill 90-92, 2006

2 Hong I, "Unlabeled uses of factor VIIa (recombinant)in pediatric patients" 67 : 1909-1919, 2010

3 김진규, "Trends in Survival and Incidence of Bronchopulmonary Dysplasia in Extremely Preterm Infants at 23-26 Weeks Gestation" 대한의학회 31 (31): 423-429, 2016

4 Poralla C, "Treatment of acute pulmonary haemorrhage in extremely preterm infants with recombinant activated factor VII" 99 : 298-300, 2010

5 Cetin H, "The use of recombinant activated factor VII in the treatment of massive pulmonary hemorrhage in a preterm infant" 17 : 213-216, 2006

6 Chang YS, "The Korean neonatal network:An overview" 30 (30): S3-S11, 2015

7 주용민, "Successful Hemostasis by the use of Recombinant Factor VIIa in Uncontrolled Active Hemorrhage of Multiple Trauma Patients" 대한응급의학회 22 (22): 22-29, 2011

8 Yilmaz D, "Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder" 25 : 301-311, 2008

9 Yen TA, "Short-term outcome of pulmonary hemorrhage in very-lowbirth-weight preterm infants" 54 : 330-334, 2013

10 Guzzetta NA, "Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients" 115 : 364-378, 2012

11 Hünseler C, "Recombinant activated factor seven in acute life-threatening bleeding in neonates:report on three cases and review of literature" 26 : 706-713, 2006

12 Dang CN, "Recombinant activated factor VIIa treatment for refractory hemorrhage in infants" 31 : 188-192, 2011

13 Fischer D, "Recombinant activated Factor VII as a hemostatic agent in very low birth weight preterms with gastrointestinal hemorrhage and disseminated intravascular coagulation" 30 : 337-342, 2008

14 Alten JA, "Pediatric off-label use of recombinant factor VIIa" 123 : 1066-1072, 2009

15 Pusateri AE, "Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma" 9 (9): S15-S24, 2005

16 Lisman T, "Mechanism of action of recombinant factor VIIa" 1 : 1138-1139, 2003

17 Cho SJ, "Initial resuscitation at delivery and short term neonatal outcomes in very-low-birth-weight infants" 30 (30): S45-S51, 2015

18 Andrew M, "Development of the human coagulation system in the full-term infant" 70 : 165-172, 1987

19 Bendapudi P, "Causes and management of pulmonary haemorrhage in the neonate" 22 : 528-531, 2012